Form 4: Immunome Director Jean Jacques Bienaime Acquires Stock Options

Director Jean Jacques Bienaime acquired 11,333 stock options in Immunome Inc. on June 13, 2024.

Summary

• Jean Jacques Bienaime, a director of Immunome Inc., acquired 11,333 stock options on June 13, 2024.
• The exercise price of these options is $16.04.
• The options vest in four quarterly installments starting June 13, 2024, and continuing until the one-year anniversary, subject to continued service with the company.
• The expiration date for these options is June 12, 2034.
• Following the transaction, Bienaime directly owns 11,333 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which is generally a positive sign of aligning management interests with shareholders, but not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule implies continued service and alignment with the company's performance over the next year.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It's common for directors and officers to receive stock options as part of their compensation, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice across the biotechnology industry to incentivize performance and align interests with shareholders.
• The vesting schedule of quarterly installments over one year is a fairly standard vesting arrangement.
• The exercise price of $16.04 would need to be compared to the market price of Immunome's stock to determine if the options are 'in the money' at the time of grant.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates